Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.

Vivos Therapeutics, Inc., a company listed in the United States, has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its Form S-1 effective as of April 26, 2024, at 4:30 P.M. The Form S-1 is a registration statement that companies must file with the SEC before they can proceed with the sale of securities to the public. The effectiveness of this form indicates that Vivos Therapeutics has met all the regulatory requirements set forth by the SEC, paving the way for a potential public offering or other securities-related activities.